PITTSBURGH, Pa. & GAITHERSBURG, Md., April 14, 2025 (GLOBE NEWSWIRE) — Longevity Health Holdings, Inc. (Nasdaq: XAGE), a company focused on human longevity and healthy aging through technologically innovative and clinically proven products in regenerative bio-aesthetics, diagnostics, and nutrition, today announced the execution of a merger agreement with 20/20 BioLabs, Inc., a leading provider of innovative laboratory tests for the early detection and the proactive management of chronic disease risk, to combine the companies in an all-stock transaction. Following the closing of the Merger, the combined company is expected to continue to trade on Nasdaq under the symbol 鈥淴AGE.鈥�
This Merger follows Longevity鈥檚 acquisition of Elevai Skincare in January 2025. The combination with 20/20 advances the Company鈥檚 March 10, 2025 announcement of its new strategy to build a footprint in diagnostics to drive synergies with its existing bio-aesthetic portfolio of products and its contemplated expansion into nutrition. Following the Closing, the Company will seek to address the epidemic of chronic disease in America under the banner 鈥�Healthy Aging, Inside and Out鈩⑩��, increasingly recognized as an urgent priority by healthcare leaders and policymakers.
Highlights of the 20/20 business are:
- Operates a CLIA Licensed, CAP Accredited lab in Gaithersburg, MD
- Offers OneTestTM, a multi-cancer early detection (MCED) blood test for more than a dozen tumor types including those of the lung, pancreas, ovaries, and liver starting at under $200. A 2024 blinded study by the U.S. National Cancer Institute demonstrated that OneTestTM, likely detects many types of cancers at earlier stages than other leading MCEDs.
- Integrated OneTestTM聽into routine physical evaluation for thousands of American firefighters and military veterans who may be at a higher risk of cancer.
- The only MCED on the market that uses capillary blood specimens for less painful sample collection.
- A pilot with Giant Food, the largest supermarket chain in the Washington, D.C. area, is expected to be announced this week.
- Expects to launch a 鈥渓ongevity test鈥� Spring 2025 that analyzes several inflammatory biomarkers associated with chronic diseases and unhealthy aging. This product will offer evidence-based diet and lifestyle recommendations to improve health span.
- Over ten consecutive quarters of sales growth.
Highlights of the post-Closing combined company are:
- Post-Closing equity valuation of the combined company is expected to be approximately $99 million, with 20/20 having a pre-money equity valuation at approximately $50 million.
- Expected to double Longevity鈥檚 fiscal year 2025 anticipated revenue from approximately $3-4 million to approximately $7-8 million.
- Expected to realize over $1 million in operational savings and synergies in fiscal year 2025.
- Longevity will offer 20/20 diagnostic tests to its network of physicians to help them design patient-specific bio-aesthetic protocols based on healthy aging.
- Longevity will offer skincare products to 20/20鈥檚 customer base of thousands of firefighters who are routinely exposed to extreme environments.
- Upon the Closing, Mr. Rajiv Shukla, Chairman and CEO of Longevity, will remain Chairman while Mr. Jonathan Cohen will be appointed CEO of the combined company.
Said Mr. Jonathan Cohen, CEO of 20/20, 鈥淲e are excited by the market, product and operational synergies between 20/20 and Longevity. We believe 20/20 is a leader in offering access to lab testing in non-traditional settings, such as homes and retail locations. We expect this Merger will expand our reach to MedSpas and other channels covered by Longevity鈥檚 existing customer base.鈥�
Said Mr. Rajiv Shukla, Chairman and CEO of Longevity, 鈥淲e are happy to announce a merger with 20/20 in line with our previously announced corporate rebranding and acquisition strategy. This merger is expected to double our fiscal year 2025 revenue forecast and put us on the path to profitability. Additionally, there are exciting product and market synergies between our product portfolios. We anticipate announcing further acquisitions in fiscal year 2025 that we believe will be value accretive to our stockholders.鈥�
About the Proposed Merger
20/20 pre-Merger stockholders are expected to own approximately 50.1% of the combined company and聽Longevity pre-Merger stockholders are expected to own approximately 49.9% of the combined company upon the Closing, prior to the additional concurrent financing transaction. The percentage of the combined company that each company鈥檚 former stockholders are expected to own may be adjusted based on the achievement of the earnout milestones, which would result in an increase in the percentage ownership of the pre-Merger 20/20 stockholders. The transaction has been unanimously approved by the Board of Directors of both companies and is expected to close in the third quarter of 2025, subject to customary closing conditions, including approvals by the stockholders of each company.
Management and Organization
Following the Merger, the combined company will be led by a management team mutually selected by the parties. The merger agreement provides that the Board of Directors of the combined company will be composed of six members, including three directors designated by 20/20 and three directors designated by Longevity.
About 20/20:
20/20 develops and commercializes innovative laboratory tests for the early detection and the proactive management of chronic disease risk. It offers the only multi-cancer early detection blood test available for under $200, accessible at home or at retail locations.
About Longevity:
Longevity Health Holdings is focused on longevity and healthy aging, encompassing the latest scientific advances in regenerative bio-aesthetics, diagnostics, and nutrition. Our products are aimed at helping people look and feel their best at any age. The Company currently offers two regenerative technologies for skin and hair health: the Carmell Secretome鈩� and Elevai ExosomesTM. The Carmell Secretome鈩� is a powerful blend of growth factors, proteins, peptides and bio-lipids derived from allogeneic human platelets, the body鈥檚 principal healing and regenerative cell. Elevai ExosomesTM are derived from human umbilical mesenchymal stem cells, which are known to contain a greater number of proteins than exosomes from non-stem cell sources.
